Predict your next investment

OrbiMed Advisors company logo
Venture Capital
FINANCE | Investment Firms & Funds
orbimed.com

See what CB Insights has to offer

Investments

711

Portfolio Exits

228

Funds

22

Service Providers

1

About OrbiMed Advisors

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages a series of venture capital funds and a family of public equity investment funds.

OrbiMed Advisors Headquarter Location

601 Lexington Avenue 54th Floor

New York, New York, 10022,

United States

212-739-6400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OrbiMed Advisors

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find OrbiMed Advisors in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

OrbiMed Advisors Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OrbiMed Advisors Rank

Latest OrbiMed Advisors News

Compass Therapeutics stock up 40% in two days following insider buys

May 12, 2022

DNY59/E+ via Getty Images In less than two trading sessions, Compass Therapeutics (NASDAQ: CMPX ) shares have risen ~40% thanks to insider purchases. SEC filings posted after Tuesday's closing bell reveal two large share purchases. CEO Thomas Schuetz  picked up 27,836 shares  on May 10 and now owns 5,153,303 in total. The other was made by Carl Gordon , founding general partner of OrbiMed Advisors and a Compass ( CMPX ) board member. On May 6, May 9, and May 10, a total of 125,359 shares were purchased and are held by OrbiMed Advisors. OrbiMed now owns 3,571,428 shares.

OrbiMed Advisors Investments

711 Investments

OrbiMed Advisors has made 711 investments. Their latest investment was in Aspen Neuroscience as part of their Series B on May 5, 2022.

CBI Logo

OrbiMed Advisors Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/9/2022

Series B

Aspen Neuroscience

$147.5M

No

4

4/19/2022

Series B

Sionna Therapeutics

$111M

Yes

4

3/21/2022

Series A - II

Tendfo

Yes

3

3/18/2022

Series A

Subscribe to see more

Subscribe to see more

10

3/1/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/9/2022

4/19/2022

3/21/2022

3/18/2022

3/1/2022

Round

Series B

Series B

Series A - II

Series A

Series C

Company

Aspen Neuroscience

Sionna Therapeutics

Tendfo

Subscribe to see more

Subscribe to see more

Amount

$147.5M

$111M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

4

3

10

10

OrbiMed Advisors Portfolio Exits

228 Portfolio Exits

OrbiMed Advisors has 228 portfolio exits. Their latest portfolio exit was ReViral on April 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/7/2022

Acquired

$99M

9

3/22/2022

IPO

2

1/7/2022

IPO

7

11/5/2021

IPO

Subscribe to see more

Subscribe to see more

10

11/5/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/7/2022

3/22/2022

1/7/2022

11/5/2021

11/5/2021

Exit

Acquired

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

9

2

7

10

10

OrbiMed Advisors Acquisitions

3 Acquisitions

OrbiMed Advisors acquired 3 companies. Their latest acquisition was Response Biomedical on June 20, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/20/2016

$99M

Take Private

1

1/1/2013

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

3/5/2007

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

0

Date

6/20/2016

1/1/2013

3/5/2007

Investment Stage

Other Venture Capital

Debt

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$99M

$99M

Note

Take Private

Subscribe to see more

Subscribe to see more

Sources

1

10

0

OrbiMed Advisors Fund History

22 Fund Histories

OrbiMed Advisors has 22 funds, including OrbiMed Private Investments VIII.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/1/2021

OrbiMed Private Investments VIII

$1,500M

2

3/1/2021

OrbiMed Royalty & Credit Opportunities III

$1,200M

2

3/1/2021

OrbiMed Asia Partners IV

$800M

4

9/5/2017

OrbiMed Asia Partners III

Subscribe to see more

Subscribe to see more

$99M

10

5/23/2016

OrbiMed Advisors Israel Fund II

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/1/2021

3/1/2021

3/1/2021

9/5/2017

5/23/2016

Fund

OrbiMed Private Investments VIII

OrbiMed Royalty & Credit Opportunities III

OrbiMed Asia Partners IV

OrbiMed Asia Partners III

OrbiMed Advisors Israel Fund II

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$1,500M

$1,200M

$800M

$99M

$99M

Sources

2

2

4

10

10

OrbiMed Advisors Service Providers

1 Service Provider

OrbiMed Advisors has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

OrbiMed Advisors Team

14 Team Members

OrbiMed Advisors has 14 team members, including current Chief Financial Officer, Trey Block.

Name

Work History

Title

Status

Anat Naschitz

Founder

Current

Trey Block

J.P. Morgan Chase & Co., The Carlyle Group, and Ernst & Young

Chief Financial Officer

Current

Daniel Rhee

Gravitas, RFA Management Company, Xerox, and U.S. Navy

Chief Technology Officer

Current

Sunny Sharma

Investor Growth Capital, Easton Capital, and Lehman Brothers

Senior Managing Director

Current

Sven H. Borho

Managing Partner

Current

Name

Anat Naschitz

Trey Block

Daniel Rhee

Sunny Sharma

Sven H. Borho

Work History

J.P. Morgan Chase & Co., The Carlyle Group, and Ernst & Young

Gravitas, RFA Management Company, Xerox, and U.S. Navy

Investor Growth Capital, Easton Capital, and Lehman Brothers

Title

Founder

Chief Financial Officer

Chief Technology Officer

Senior Managing Director

Managing Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.